

Supplementary table 1. Cumulative incidence plot for irAEs grade \geq 3

	6-month grade 3 irAE rate (95% CI)	1-year grade 3 irAE rate (95% CI)
All Patients	7.5% (5.0% to 10.0%)	10.6% (7.6% to 13.6%)
mRCC	8.5% (5.0% to 12.0%)	13.5% (9.0% to 18.0%)
mUC	6.2% (2.8% to 9.6%)	6.8% (3.2% to 10.5%)

irAEs: Immune-related adverse events; mRCC: metastatic renal cell carcinoma; mUC: metastatic urothelial carcinoma; CI: confidence interval